Gd(III) chelates for MRI contrast agents: from high relaxivity to “smart”, from blood pool to blood–brain barrier permeable

Paramagnetic Gd(III) chelate contrast agents have been extensively used to enhance the signal of MRI scans for the last three decades. The use of Gd(III) chelate contrast agents is projected to increase as new agents and applications arise, thanks to the favorable combination of a large magnetic moment and long electron spin relaxation time of the Gd(III) ion. The relaxivity and stability of Gd(III) chelates are the primary requisites for the development of contrast agents as both small doses and low release of free Gd(III) ions will reduce the toxicity. The physico-chemical parameters and structure-related relaxation mechanisms provide the strategies for chelate design. The higher relaxivity and efficacy of the contrast agent can be improved by designing pH-, metal ion-, enzyme- or small biomolecule-dependent “smart” contrast agents. Through conjugation to biomacromolecules such as polymers, dendrimers or non-covalent binding to plasma proteins, contrast agents could increase the blood half-life and can be used for contrast-enhanced MRI. When conjugated to certain diagnostic or therapeutic proteins, low molecular weight Gd(III) chelates could cross the blood–brain barrier (BBB) by means of a receptor-mediated transport system or receptor-mediated transcytosis.

[1]  B. Hyman,et al.  Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging , 2011, Proceedings of the National Academy of Sciences.

[2]  Yi Lu,et al.  A smart magnetic resonance imaging contrast agent responsive to adenosine based on a DNA aptamer-conjugated gadolinium complex. , 2011, Chemical communications.

[3]  Chang-Tong Yang,et al.  Development of Intravascular Contrast Agents for MRI Using Gadolinium Chelates , 2011, ChemMedChem.

[4]  M. Brechbiel,et al.  Preparation, characterization and in vivo assessment of Gd-albumin and Gd-dendrimer conjugates as intravascular contrast-enhancing agents for MRI. , 2011, Journal of inorganic biochemistry.

[5]  Piper J. Klemm,et al.  Conjugation effects of various linkers on Gd(III) MRI contrast agents with dendrimers: optimizing the hydroxypyridinonate (HOPO) ligands with nontoxic, degradable esteramide (EA) dendrimers for high relaxivity. , 2011, Journal of the American Chemical Society.

[6]  R. Deane,et al.  Low‐density lipoprotein receptor‐related protein‐1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid β‐peptide elimination from the brain , 2010, Journal of neurochemistry.

[7]  M. Botta,et al.  AAZTA-based bifunctional chelating agents for the synthesis of multimeric/dendrimeric MRI contrast agents. , 2010, Organic & biomolecular chemistry.

[8]  M. Bernardo,et al.  Comparison of MRI properties between derivatized DTPA and DOTA gadolinium-dendrimer conjugates. , 2010, Bioorganic & medicinal chemistry.

[9]  M. Brechbiel,et al.  Poly(amidoamine) dendrimer based MRI contrast agents exhibiting enhanced relaxivities derived via metal preligation techniques. , 2010, Bioconjugate chemistry.

[10]  Ciprian Catana,et al.  Bimodal MR-PET agent for quantitative pH imaging. , 2010, Angewandte Chemie.

[11]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[12]  S. Baker,et al.  A copper-activated magnetic resonance imaging contrast agent with improved turn-on relaxivity response and anion compatibility. , 2010, Dalton transactions.

[13]  Andrew Tsourkas,et al.  Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. , 2010, Angewandte Chemie.

[14]  E. Que,et al.  Responsive magnetic resonance imaging contrast agents as chemical sensors for metals in biology and medicine. , 2010, Chemical Society reviews.

[15]  A Dean Sherry,et al.  A new gadolinium-based MRI zinc sensor. , 2009, Journal of the American Chemical Society.

[16]  Emmanuel L Barbier,et al.  Characterization of Tumor Angiogenesis in Rat Brain Using Iron-Based Vessel Size Index MRI in Combination with Gadolinium-Based Dynamic Contrast-Enhanced MRI , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  M. Brechbiel,et al.  A new approach in the preparation of dendrimer-based bifunctional diethylenetriaminepentaacetic acid MR contrast agent derivatives. , 2009, Bioconjugate chemistry.

[18]  Suzanne L Baker,et al.  Copper-responsive magnetic resonance imaging contrast agents. , 2009, Journal of the American Chemical Society.

[19]  Val M. Runge,et al.  Brain Tumor Enhancement in Magnetic Resonance Imaging at 3 Tesla: Intraindividual Comparison of Two High Relaxivity Macromolecular Contrast Media With a Standard Extracellular Gd-Chelate in a Rat Brain Tumor Model , 2009, Investigative radiology.

[20]  Peter Caravan,et al.  Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. , 2009, Contrast media & molecular imaging.

[21]  Sophie Laurent,et al.  Classification and basic properties of contrast agents for magnetic resonance imaging. , 2009, Contrast media & molecular imaging.

[22]  Ralph Weissleder,et al.  Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase , 2008, Proceedings of the National Academy of Sciences.

[23]  Thomas J Meade,et al.  Mechanisms of ZnII-activated magnetic resonance imaging agents. , 2008, Inorganic chemistry.

[24]  Peter Caravan,et al.  Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. , 2008, Chemistry.

[25]  R. Béliveau,et al.  Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2 , 2008, Journal of neurochemistry.

[26]  N. Logothetis,et al.  Smart Magnetic Resonance Imaging Agents that Sense Extracellular Calcium Fluctuations , 2008, Chembiochem : a European journal of chemical biology.

[27]  N. Logothetis,et al.  Synthesis and characterization of a smart contrast agent sensitive to calcium. , 2008, Chemical communications.

[28]  Jing-Huei Lee,et al.  A beta-cyclodextrin "click cluster" decorated with seven paramagnetic chelates containing two water exchange sites. , 2008, Bioconjugate chemistry.

[29]  P. Hermann,et al.  Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. , 2008, Dalton transactions.

[30]  M. Garwood,et al.  Selective Contrast Enhancement of Individual Alzheimer’s Disease Amyloid Plaques Using a Polyamine and Gd-DOTA Conjugated Antibody Fragment Against Fibrillar Aβ42 for Magnetic Resonance Molecular Imaging , 2008, Pharmaceutical Research.

[31]  R. D. Bolskar Gadofullerene MRI contrast agents. , 2008, Nanomedicine.

[32]  P. Libby,et al.  Activatable Magnetic Resonance Imaging Agent Reports Myeloperoxidase Activity in Healing Infarcts and Noninvasively Detects the Antiinflammatory Effects of Atorvastatin on Ischemia-Reperfusion Injury , 2008, Circulation.

[33]  L. Helm,et al.  A benzene-core trinuclear GdIII complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field. , 2008, Dalton transactions.

[34]  R. Muthupillai,et al.  Gadonanotubes as ultrasensitive pH-smart probes for magnetic resonance imaging. , 2008, Nano letters.

[35]  K. Hanaoka,et al.  A Gd3+-based magnetic resonance imaging contrast agent sensitive to beta-galactosidase activity utilizing a receptor-induced magnetization enhancement (RIME) phenomenon. , 2008, Chemistry.

[36]  Li Li,et al.  Micelles based on biodegradable poly(L-glutamic acid)-b-polylactide with paramagnetic Gd ions chelated to the shell layer as a potential nanoscale MRI-visible delivery system. , 2007, Biomacromolecules.

[37]  N. Logothetis,et al.  Facile synthesis and relaxation properties of novel bispolyazamacrocyclic Gd3+ complexes: an attempt towards calcium-sensitive MRI contrast agents. , 2008, Inorganic chemistry.

[38]  Yuguo Li,et al.  Design and characterization of a new irreversible responsive PARACEST MRI contrast agent that detects nitric oxide , 2007, Magnetic resonance in medicine.

[39]  A. Tanimoto,et al.  Novel 15-crown-5 ether or beta-diketone incorporated gadolinium complexes for the detection of potassium ions or magnesium and calcium ions. , 2007, The Analyst.

[40]  G. Liu,et al.  Synthesis and characterization of a new bioactivated paramagnetic gadolinium(III) complex [Gd(DOTA-FPG)(H2O)] for tracing gene expression. , 2007, Bioconjugate chemistry.

[41]  M. Botta,et al.  An esterase-activated magnetic resonance contrast agent. , 2007, Chemical communications.

[42]  A. Tanimoto,et al.  Basic Design and Synthesis of Sulfonated Contrast Agents for Magnetic Resonance Imaging Based on Gadolinium Complexes , 2007, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[43]  Nikos K. Logothetis,et al.  Towards extracellular Ca2+ sensing by MRI: synthesis and calcium-dependent 1H and 17O relaxation studies of two novel bismacrocyclic Gd3+ complexes , 2007, JBIC Journal of Biological Inorganic Chemistry.

[44]  T. Meade,et al.  The synthesis and in vitro testing of a zinc-activated MRI contrast agent , 2007, Proceedings of the National Academy of Sciences.

[45]  G. Curran,et al.  Pharmacokinetics and Amyloid Plaque Targeting Ability of a Novel Peptide-Based Magnetic Resonance Contrast Agent in Wild-Type and Alzheimer's Disease Transgenic Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[46]  E. W. Meijer,et al.  Dendrimers and magnetic resonance imaging , 2007 .

[47]  M. Ramirez-Alvarado,et al.  In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques , 2007, Journal of neurochemistry.

[48]  E. Jeong,et al.  Modification of Gd‐DTPA cystine copolymers with PEG‐1000 optimizes pharmacokinetics and tissue retention for magnetic resonance angiography , 2007, Magnetic resonance in medicine.

[49]  Katherine S. Lovejoy,et al.  Water-soluble porphyrins as a dual-function molecular imaging platform for MRI and fluorescence zinc sensing , 2007, Proceedings of the National Academy of Sciences.

[50]  Paul Jurek,et al.  Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH. , 2007, Inorganic chemistry.

[51]  Klaas Nicolay,et al.  MRI contrast agents: current status and future perspectives. , 2007, Anti-cancer agents in medicinal chemistry.

[52]  R. Muthupillai,et al.  Gadofullerenes as nanoscale magnetic labels for cellular MRI. , 2007, Contrast media & molecular imaging.

[53]  M. Botta,et al.  Highly soluble tris-hydroxypyridonate Gd(III) complexes with increased hydration number, fast water exchange, slow electronic relaxation, and high relaxivity. , 2007, Journal of the American Chemical Society.

[54]  D. Tomalia,et al.  Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. , 2007, Biochemical Society transactions.

[55]  B. K. Park,et al.  Adrenal tumors with late enhancement on CT and MRI , 2007, Abdominal Imaging.

[56]  Claudia Weidensteiner,et al.  Physicochemical and MRI characterization of Gd3+-loaded polyamidoamine and hyperbranched dendrimers , 2007, JBIC Journal of Biological Inorganic Chemistry.

[57]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[58]  Christopher J. Chang,et al.  A smart magnetic resonance contrast agent for selective copper sensing. , 2006, Journal of the American Chemical Society.

[59]  Y. Ni,et al.  Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity. , 2006, Contrast media & molecular imaging.

[60]  Dennis L Parker,et al.  Biodegradable cystamine spacer facilitates the clearance of Gd(III) chelates in poly(glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging. , 2006, Magnetic resonance imaging.

[61]  M. Botta,et al.  Fe(III)-templated Gd(III) self-assemblies-a new route toward macromolecular MRI contrast agents. , 2006, Journal of the American Chemical Society.

[62]  V. Jacques,et al.  Auto-assembling of ditopic macrocyclic lanthanide chelates with transition-metal ions. Rigid multimetallic high relaxivity contrast agents for magnetic resonance imaging. , 2006, Inorganic chemistry.

[63]  Enzo Terreno,et al.  High sensitivity lanthanide(III) based probes for MR-medical imaging , 2006 .

[64]  D. Parker,et al.  Gd-DTPA l-Cystine Bisamide Copolymers as Novel Biodegradable Macromolecular Contrast Agents for MR Blood Pool Imaging , 2006, Pharmaceutical Research.

[65]  Peter Caravan,et al.  Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. , 2006, Chemical Society reviews.

[66]  Lisheng Cai,et al.  Imaging and In Vivo Quantitation of β-Amyloid: An Exemplary Biomarker for Alzheimer’s Disease? , 2006, Biological Psychiatry.

[67]  S. Cho,et al.  Diethylenetriaminepentaacetic acid-gadolinium (DTPA-Gd)-conjugated polysuccinimide derivatives as magnetic resonance imaging contrast agents. , 2006, Bioconjugate chemistry.

[68]  Gabriel P Krestin,et al.  Magnetic Resonance Macromolecular Agents for Monitoring Tumor Microvessels and Angiogenesis Inhibition , 2006, Investigative radiology.

[69]  P. Anelli,et al.  Gadocoletic Acid Trisodium Salt (B22956/1): A New Blood Pool Magnetic Resonance Contrast Agent With Application in Coronary Angiography , 2006, Investigative radiology.

[70]  A. Mohs,et al.  Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents , 2006, International journal of nanomedicine.

[71]  Walter H Backes,et al.  Evaluation of Gd(III)DTPA‐terminated poly(propylene imine) dendrimers as contrast agents for MR imaging , 2006, NMR in biomedicine.

[72]  Robert J Gillies,et al.  High resolution pHe imaging of rat glioma using pH‐dependent relaxivity , 2006, Magnetic resonance in medicine.

[73]  É. Tóth,et al.  A starburst-shaped heterometallic compound incorporating six densely packed gd(3+) ions. , 2006, Chemistry.

[74]  Y. Wadghiri Contrast agents. , 2006, Radiologic technology.

[75]  Hisataka Kobayashi,et al.  Nano-sized MRI contrast agents with dendrimer cores. , 2005, Advanced drug delivery reviews.

[76]  B. Jebasingh,et al.  Synthesis and relaxivity studies of a tetranuclear gadolinium(III) complex of DO3A as a contrast-enhancing agent for MRI. , 2005, Inorganic chemistry.

[77]  A Dean Sherry,et al.  Selective sensing of zinc ions with a PARACEST contrast agent. , 2005, Angewandte Chemie.

[78]  Anna Moore,et al.  Crossing the blood–brain barrier: A potential application of myristoylated polyarginine for in vivo neuroimaging , 2005, NeuroImage.

[79]  D. Parker,et al.  Contrast‐enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor‐bearing mice , 2005, Magnetic resonance in medicine.

[80]  R. Weissleder,et al.  DTPA-bisamide-based MR sensor agents for peroxidase imaging. , 2005, Organic letters.

[81]  M. Port,et al.  In vitro Relaxometric and Luminescence Characterization of P792 (Gadomelitol, Vistarem®), an Efficient and Rapid Clearance Blood Pool MRI Contrast Agent , 2005 .

[82]  Alain Borel,et al.  High relaxivity confined to a small molecular space: a metallostar-based, potential MRI contrast agent. , 2005, Angewandte Chemie.

[83]  M. Özmen,et al.  Efficacy of transvaginal contrast-enhanced MRI in the early staging of cervical carcinoma , 2005, European Radiology.

[84]  B. Sitharaman,et al.  Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. , 2005, Journal of the American Chemical Society.

[85]  M. Botta,et al.  Dendrimeric gadolinium chelate with fast water exchange and high relaxivity at high magnetic field strength. , 2005, Journal of the American Chemical Society.

[86]  M. Botta,et al.  Efficient relaxivity enhancement in dendritic gadolinium complexes: effective motional coupling in medium molecular weight conjugates. , 2005, Chemical communications.

[87]  É. Tóth,et al.  Rotational dynamics account for pH-dependent relaxivities of PAMAM dendrimeric, Gd-based potential MRI contrast agents. , 2005, Chemistry.

[88]  E. Gianolio,et al.  Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates. , 2004, Current pharmaceutical biotechnology.

[89]  M. Lowe Activated MR contrast agents. , 2004, Current pharmaceutical biotechnology.

[90]  B. Sitharaman,et al.  Gd@C60[C(COOH)2]10 and Gd@C60(OH)x: Nanoscale Aggregation Studies of Two Metallofullerene MRI Contrast Agents in Aqueous Solution , 2004 .

[91]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[92]  Eliana Gianolio,et al.  [Gd-AAZTA]-: a new structural entry for an improved generation of MRI contrast agents. , 2004, Inorganic chemistry.

[93]  R. Price,et al.  Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent. , 2004, Bioconjugate chemistry.

[94]  D. Parker,et al.  PEG-g-poly(GdDTPA-co-L-cystine): a biodegradable macromolecular blood pool contrast agent for MR imaging. , 2004, Bioconjugate chemistry.

[95]  R.J. Gillies,et al.  pH imaging , 2004, IEEE Engineering in Medicine and Biology Magazine.

[96]  J. Klaveness,et al.  Biodistribution of pH-responsive liposomes for MRI and a novel approach to improve the pH-responsiveness. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[97]  S. DeKosky,et al.  O3-03-05 Human amyloid-imaging studies in controls, mild cognitive impairment and Alzheimer's disease using Pittsburg compound-B , 2004, Neurobiology of Aging.

[98]  G. Curran,et al.  Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. , 2004, Biochemistry.

[99]  W. Klunk,et al.  Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain , 2004 .

[100]  A. Bjørnerud,et al.  Novel pH‐sensitive paramagnetic liposomes with improved MR properties , 2004, Magnetic resonance in medicine.

[101]  A. Menrad,et al.  Molecular Imaging of Tumor Angiogenesis , 2004, Annals of the New York Academy of Sciences.

[102]  A. Merbach,et al.  Novel heteroditopic chelate for self-assembled gadolinium(III) complex with high relaxivity. , 2004, Chemical communications.

[103]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[104]  D. Parker,et al.  Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI , 2004, Magnetic resonance in medicine.

[105]  S. Gambhir,et al.  Gene Therapy Progress and Prospects: Noninvasive imaging of gene therapy in living subjects , 2004, Gene Therapy.

[106]  Michal Neeman,et al.  Structural, functional, and molecular MR imaging of the microvasculature. , 2003, Annual review of biomedical engineering.

[107]  A Dean Sherry,et al.  A paramagnetic CEST agent for imaging glucose by MRI. , 2003, Journal of the American Chemical Society.

[108]  A. Sherry,et al.  pH-sensitive modulation of the second hydration sphere in lanthanide(III) tetraamide-DOTA complexes: a novel approach to smart MR contrast media. , 2003, Chemistry.

[109]  Thomas Wisniewski,et al.  Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging , 2003, Magnetic resonance in medicine.

[110]  Frank Fischbach,et al.  Clinical results of CsI-detector-based dual-exposure dual energy in chest radiography , 2003, European Radiology.

[111]  R. Price,et al.  First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent. , 2003, Journal of the American Chemical Society.

[112]  H. Shinohara,et al.  Lanthanoid endohedral metallofullerenols for MRI contrast agents. , 2003, Journal of the American Chemical Society.

[113]  G. Palmisano,et al.  Designing Novel Contrast Agents for Magnetic Resonance Imaging. Synthesis and Relaxometric Characterization of three Gadolinium(III) Complexes Based on Functionalized Pyridine-Containing Macrocyclic Ligands , 2003 .

[114]  Robert J Gillies,et al.  Renal and systemic pH imaging by contrast‐enhanced MRI , 2003, Magnetic resonance in medicine.

[115]  R. Felix,et al.  Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer , 2003, European Radiology.

[116]  T. Chenevert,et al.  Magnetic resonance imaging in cancer research. , 2002, European journal of cancer.

[117]  Gregory S Karczmar,et al.  MRI of the tumor microenvironment , 2002, Journal of magnetic resonance imaging : JMRI.

[118]  A. Padhani Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.

[119]  Y. Urano,et al.  Design and synthesis of a novel magnetic resonance imaging contrast agent for selective sensing of zinc ion. , 2002, Chemistry & biology.

[120]  Claudio Luchinat,et al.  Mechanistic studies of a calcium-dependent MRI contrast agent. , 2002, Inorganic chemistry.

[121]  Enzo Terreno,et al.  A paramagnetic MRI-CEST agent responsive to lactate concentration. , 2002, Journal of the American Chemical Society.

[122]  Peter Caravan,et al.  The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. , 2002, Journal of the American Chemical Society.

[123]  Michal Neeman,et al.  Functional and molecular MR imaging of angiogenesis: Seeing the target, seeing it work , 2002, Journal of cellular biochemistry. Supplement.

[124]  T. Helbich,et al.  MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS‐325) with correlations to histopathology , 2001, Journal of magnetic resonance imaging : JMRI.

[125]  Peter Caravan,et al.  Enzyme-Activated Gd3+ Magnetic Resonance Imaging Contrast Agents with a Prominent Receptor-Induced Magnetization Enhancement. , 2001, Angewandte Chemie.

[126]  M V Knopp,et al.  Dynamic contrast-enhanced magnetic resonance imaging in oncology. , 2001, Topics in magnetic resonance imaging : TMRI.

[127]  S Aime,et al.  pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. , 2001, Journal of the American Chemical Society.

[128]  M D Schnall,et al.  MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. , 2001, Radiology.

[129]  A. Bjørnerud,et al.  pH-sensitive paramagnetic liposomes as MRI contrast agents: in vitro feasibility studies. , 2001, Magnetic resonance imaging.

[130]  S. Laurent,et al.  Stereospecific binding of MRI contrast agents to human serum albumin: the case of Gd-(S)-EOB-DTPA (Eovist) and its (R) isomer , 2001, JBIC Journal of Biological Inorganic Chemistry.

[131]  Y. Urano,et al.  Selective sensing of zinc ions with a novel magnetic resonance imaging contrast agent , 2001 .

[132]  M. Brechbiel,et al.  Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. , 2001, Bioconjugate chemistry.

[133]  Jide Xu,et al.  Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents. , 2000, Inorganic chemistry.

[134]  Thorfinnur Gunnlaugsson,et al.  The Selectivity of Reversible Oxy-Anion Binding in Aqueous Solution at a Chiral Europium and Terbium Center: Signaling of Carbonate Chelation by Changes in the Form and Circular Polarization of Luminescence Emission , 2000 .

[135]  K. Raymond,et al.  Synthesis of a ligand based upon a new entry into the 3-hydroxy-N-alkyl-2(1H)-pyridinone ring system and thermodynamic evaluation of its gadolinium complex. , 2000, Inorganic chemistry.

[136]  P. Anelli,et al.  Sulfonamide‐Functionalized Gadolinium DTPA Complexes as Possible Contrast Agents for MRI: A Relaxometric Investigation , 2000 .

[137]  Scott E. Fraser,et al.  In vivo visualization of gene expression using magnetic resonance imaging , 2000, Nature Biotechnology.

[138]  Sherry,et al.  A Novel pH-Sensitive MRI Contrast Agent. , 1999, Angewandte Chemie.

[139]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[140]  V. Jacques,et al.  Designing new MRI contrast agents: a coordination chemistry challenge , 1999 .

[141]  Weissleder,et al.  Approaches and agents for imaging the vascular system. , 1999, Advanced drug delivery reviews.

[142]  S. Fraser,et al.  A Calcium-Sensitive Magnetic Resonance Imaging Contrast Agent , 1999 .

[143]  M. Botta,et al.  A macromolecular Gd(III) complex as pH-responsive relaxometric probe for MRI applications , 1999 .

[144]  L. Helm,et al.  Direct assessment of water exchange on a Gd(III) chelate bound to a protein , 1998, JBIC Journal of Biological Inorganic Chemistry.

[145]  R. Ranganathan,et al.  New multimeric magnetic resonance imaging agents. , 1998, Investigative radiology.

[146]  D C Peters,et al.  Steady-state and dynamic MR angiography with MS-325: initial experience in humans. , 1998, Radiology.

[147]  R. Dolan,et al.  MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.

[148]  Enzo Terreno,et al.  Lanthanide(III) chelates for NMR biomedical applications , 1998 .

[149]  R. Lauffer,et al.  Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. , 1997, Investigative radiology.

[150]  S. Laurent,et al.  A multinuclear MR study of Gd‐EOB‐DTPA: Comprehensive preclinical characterization of an organ specific MRI contrast agent , 1997, Magnetic resonance in medicine.

[151]  Scott E. Fraser,et al.  A SMART MAGNETIC RESONANCE IMAGING AGENT THAT REPORTS ON SPECIFIC ENZYMATIC ACTIVITY , 1997 .

[152]  M. Botta,et al.  Gd(III) complexes as contrast agents for magnetic resonance imaging: a proton relaxation enhancement study of the interaction with human serum albumin , 1996, JBIC Journal of Biological Inorganic Chemistry.

[153]  Jurriaan Huskens,et al.  Lanthanide induced shifts and relaxation rate enhancements , 1996 .

[154]  W. Schima,et al.  Contrast-enhanced MR imaging. , 1996, Clinical radiology.

[155]  R. Weissleder,et al.  Long-circulating blood pool imaging agents , 1995 .

[156]  M. Hynes,et al.  Gadolinium(III) di- and tetrachelates designed for in vivo noncovalent complexation with plasma proteins: a novel molecular design for blood pool MRI contrast enhancing agents. , 1995, Bioconjugate chemistry.

[157]  Jide Xu,et al.  Gadolinium complex of tris[(3-hydroxy-1-methyl- 2-oxo-1,2-didehydropyridine-4-carboxamido)ethyl]-amine: A New Class of gadolinium magnetic resonance relaxation agents , 1995 .

[158]  R. Vré,et al.  Invited review: biophysical properties and clinical applications of magnetic resonance imaging contrast agents. , 1995, The British journal of radiology.

[159]  R. Brasch,et al.  Effect of varying the molecular weight of the MR contrast agent Gd‐DTPA‐polylysine on blood pharmacokinetics and enhancement patterns , 1994, Journal of magnetic resonance imaging : JMRI.

[160]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[161]  Jonathan L. Sessler,et al.  Gadolinium(III) texaphyrin : a novel MRI contrast agent , 1993 .

[162]  M. Tweedle Gadolinium chelates as relaxation agents in magnetic resonance imaging , 1992 .

[163]  H. Weinmann,et al.  A new lipophilic gadolinium chelate as a tissue‐specific contrast medium for MRI , 1991, Magnetic resonance in medicine.

[164]  H. Weinmann,et al.  In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. , 1991, Investigative radiology.

[165]  Seymour H. Koenig,et al.  Field-cycling relaxometry of protein solutions and tissue: Implications for MRI , 1990 .

[166]  J. Thrall,et al.  Pharmaceuticals in medical imaging : radiopaque contrast media, radiopharmaceuticals, enhancement agents for magnetic resonance imaging and ultrasound , 1990 .

[167]  R. Lauffer,et al.  Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design , 1987 .

[168]  W. Krause,et al.  Contrast agents. , 1985, Magnetic resonance imaging.

[169]  T. Brady,et al.  Preparation and water relaxation properties of proteins labeled with paramagnetic metal chelates. , 1985, Magnetic resonance imaging.